Key result
Pharmacologic agonists directed against various PPARs have a beneficial impact on metabolic risk factors in diabetes, with potential implications for cardiovascular risk.
Why the study?
Do PPAR agonists improve cardiovascular risk in diabetic cohorts?
Do PPAR agonists improve cardiovascular risk in diabetic cohorts?
This review highlights the potential of PPAR agonists to modify metabolic risk factors and potentially improve cardiovascular outcomes in patients with diabetes.
May support metabolic management in diabetes; leaves open whether PPAR agonists reduce cardiovascular events.
Diabetes is associated with a range of metabolic abnormalities including insulin resistance, atherogenic dyslipidemia, hypertension, and inflammation. These factors are likely to underlie the adverse cardiovascular outcome typically observed in diabetic cohorts. The family of peroxisome proliferator-activated receptors (PPARs) have been implicated in the regulation of a number of physiologic and metabolic pathways. Pharmacologic agonists directed against various PPARs have been shown to have a beneficial impact on these metabolic risk factors. The potential impact on cardiovascular risk with the use of PPAR agonists will be reviewed.
No takes yet. Share an insight, caveat, or question.
Cavender et al. (2010) conducted a review in Diabetes. PPAR agonists was evaluated. Pharmacologic agonists directed against various PPARs have a beneficial impact on metabolic risk factors in diabetes, with potential implications for cardiovascular risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: